Literature DB >> 33190560

Treatment Patterns and Blood Pressure Control With Initiation of Combination Versus Monotherapy Antihypertensive Regimens.

Jaejin An1, Tiffany Luong1, Lei Qian1, Rong Wei1, Ran Liu1, Paul Muntner2, Jeffrey Brettler3, Marc G Jaffe4, Andrew E Moran5,6, Kristi Reynolds1,7.   

Abstract

Many patients with hypertension require 2 or more drug classes to achieve their blood pressure (BP) goal. We compared antihypertensive medication treatment patterns and BP control between patients who initiated combination therapy versus monotherapy. We identified adults with hypertension enrolled in a US integrated healthcare system who initiated antihypertensive medication between 2008 and 2014. Patient demographics, clinical characteristics, antihypertensive medication, and BP were extracted from electronic health records. Antihypertensive medication patterns and multivariable adjusted prevalence ratios (PRs) of achieving the 2017 American College of Cardiology/American Heart Association guideline-recommended BP <130/80 mm Hg were evaluated for 2 years following treatment initiation. Of 135 971 patients, 43% initiated antihypertensive combination therapy (35% ACE [angiotensin converting enzyme] inhibitor (ACEI)-thiazide diuretics; 8% with other combinations) and 57% initiated monotherapy (22% ACEIs; 16% thiazide diuretics; 11% β blockers; 8% calcium channel blockers). After multivariable adjustment including premedication BP levels, patients who initiated ACEI-thiazide diuretic combination therapy were more likely to achieve BP <130/80 mm Hg compared with their counterparts who initiated monotherapy with ACEI (PR, 1.10 [95% CI, 1.08-1.12]), thiazide diuretic (PR, 1.21 [95% CI, 1.18-1.24]), β blocker (PR, 1.17 [95% CI, 1.14-1.20]), or calcium channel blocker (PR, 1.25 [95% CI, 1.22-1.29]). Compared with initiating monotherapy, patients initiating ACEI-thiazide diuretic combination therapy were more likely to achieve BP goals.

Entities:  

Keywords:  adult; blood pressure; goal; hypertension; prevalence

Mesh:

Substances:

Year:  2020        PMID: 33190560     DOI: 10.1161/HYPERTENSIONAHA.120.15462

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

1.  Racial and Ethnic Differences in Blood Pressure Among US Adults, 1999-2018.

Authors:  Shakia T Hardy; Ligong Chen; Andrea L Cherrington; Nathalie Moise; Byron C Jaeger; Kathryn Foti; Swati Sakhuja; Gregory Wozniak; Marwah Abdalla; Paul Muntner
Journal:  Hypertension       Date:  2021-11-01       Impact factor: 10.190

2.  Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention Among Patients With Hypertension in the United Kingdom.

Authors:  Tianze Jiao; Robert W Platt; Antonios Douros; Kristian B Filion
Journal:  Am J Hypertens       Date:  2022-01-05       Impact factor: 3.080

3.  Development of energy-rich protein bars and in vitro determination of angiotensin I-converting enzyme inhibitory antihypertensive activities.

Authors:  Sidra Jabeen; Faiqa Javed; Navam S Hettiarachchy; Amna Sahar; Aysha Sameen; Moazzam Rafiq Khan; Azhari Siddeeg; Ayesha Riaz; Rana Muhammad Aadil
Journal:  Food Sci Nutr       Date:  2022-01-23       Impact factor: 2.863

4.  Clinicians' prescribing pattern, rate of patients' medication adherence and its determinants among adult hypertensive patients at Jimma University Medical Center: Prospective cohort study.

Authors:  Bekalu Kebede Simegn; Legese Chelkeba; Bekalu Dessie Alamirew
Journal:  PLoS One       Date:  2021-11-15       Impact factor: 3.240

5.  Non-persistence to antihypertensive drug therapy in Lithuania.

Authors:  Indre Treciokiene; Nomeda Bratcikoviene; Jolanta Gulbinovic; Bjorn Wettermark; Katja Taxis
Journal:  Eur J Clin Pharmacol       Date:  2022-08-02       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.